Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

The impact of work-related stress on medication errors in Eastern Region Saudi Arabia.

Salam A, Segal DM, Abu-Helalah MA, Gutierrez ML, Joosub I, Ahmed W, Bibi R, Clarke E, Qarni AAA.

Int J Qual Health Care. 2018 May 7. doi: 10.1093/intqhc/mzy097. [Epub ahead of print]

PMID:
29741703
2.

Resolved-Sideband Laser Cooling in a Penning Trap.

Goodwin JF, Stutter G, Thompson RC, Segal DM.

Phys Rev Lett. 2016 Apr 8;116(14):143002. doi: 10.1103/PhysRevLett.116.143002. Epub 2016 Apr 6.

3.

Control of the conformations of ion Coulomb crystals in a Penning trap.

Mavadia S, Goodwin JF, Stutter G, Bharadia S, Crick DR, Segal DM, Thompson RC.

Nat Commun. 2013;4:2571. doi: 10.1038/ncomms3571.

4.

The structural biology of Toll-like receptors.

Botos I, Segal DM, Davies DR.

Structure. 2011 Apr 13;19(4):447-59. doi: 10.1016/j.str.2011.02.004. Review.

5.

TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.

Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, Wang Y, Venzon D, Epstein SL, Segal DM.

J Immunol. 2011 Feb 15;186(4):2422-9. doi: 10.4049/jimmunol.1002845. Epub 2011 Jan 17.

6.

Dimerization of Toll-like receptor 3 (TLR3) is required for ligand binding.

Wang Y, Liu L, Davies DR, Segal DM.

J Biol Chem. 2010 Nov 19;285(47):36836-41. doi: 10.1074/jbc.M110.167973. Epub 2010 Sep 22.

7.

Fast shuttling of ions in a scalable Penning trap array.

Crick DR, Donnellan S, Ananthamurthy S, Thompson RC, Segal DM.

Rev Sci Instrum. 2010 Jan;81(1):013111. doi: 10.1063/1.3276699.

PMID:
20113085
8.

The toll-like receptor 3:dsRNA signaling complex.

Botos I, Liu L, Wang Y, Segal DM, Davies DR.

Biochim Biophys Acta. 2009 Sep-Oct;1789(9-10):667-74. doi: 10.1016/j.bbagrm.2009.06.005. Epub 2009 Jul 9. Review.

9.

Double well potentials and quantum phase transitions in ion traps.

Retzker A, Thompson RC, Segal DM, Plenio MB.

Phys Rev Lett. 2008 Dec 31;101(26):260504.

PMID:
19437628
10.

Predicting Toll-like receptor structures and characterizing ligand binding.

Leonard JN, Bell JK, Segal DM.

Methods Mol Biol. 2009;517:55-67. doi: 10.1007/978-1-59745-541-1_4.

PMID:
19378017
11.

Two-ion Coulomb crystals of Ca + in a Penning trap.

Crick DR, Ohadi H, Bhatti I, Thompson RC, Segal DM.

Opt Express. 2008 Feb 18;16(4):2351-62.

PMID:
18542313
12.

Measurement of intercellular conjugates by flow cytometry.

Segal DM.

Curr Protoc Immunol. 2001 May;Chapter 5:Unit 5.6. doi: 10.1002/0471142735.im0506s14.

PMID:
18432800
13.

Production of bispecific antibodies.

Segal DM, Bast BJ.

Curr Protoc Immunol. 2001 May;Chapter 2:Unit 2.13. doi: 10.1002/0471142735.im0213s14. Review.

PMID:
18432765
14.

Structural basis of toll-like receptor 3 signaling with double-stranded RNA.

Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, Davies DR.

Science. 2008 Apr 18;320(5874):379-81. doi: 10.1126/science.1155406.

15.

The TLR3 signaling complex forms by cooperative receptor dimerization.

Leonard JN, Ghirlando R, Askins J, Bell JK, Margulies DH, Davies DR, Segal DM.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):258-63. doi: 10.1073/pnas.0710779105. Epub 2008 Jan 2.

16.

The molecular structure of the TLR3 extracellular domain.

Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Davies DR, Segal DM.

J Endotoxin Res. 2006;12(6):375-8.

PMID:
17254392
17.

Neisseria meningitidis type C capsular polysaccharide inhibits lipooligosaccharide-induced cell activation by binding to CD14.

Kocabas C, Katsenelson N, Kanswal S, Kennedy MN, Cui X, Blake MS, Segal DM, Akkoyunlu M.

Cell Microbiol. 2007 May;9(5):1297-310. Epub 2007 Jan 22.

PMID:
17250593
18.

Human conjunctival epithelial cells lack lipopolysaccharide responsiveness due to deficient expression of MD2 but respond after interferon-gamma priming or soluble MD2 supplementation.

Talreja J, Dileepan K, Puri S, Kabir MH, Segal DM, Stechschulte DJ, Dileepan KN.

Inflammation. 2005 Dec;29(4-6):170-81.

PMID:
17093906
19.

Cytoplasmic targeting motifs control localization of toll-like receptor 9.

Leifer CA, Brooks JC, Hoelzer K, Lopez J, Kennedy MN, Mazzoni A, Segal DM.

J Biol Chem. 2006 Nov 17;281(46):35585-92. Epub 2006 Sep 21.

20.

Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells.

Mazzoni A, Siraganian RP, Leifer CA, Segal DM.

J Immunol. 2006 Sep 15;177(6):3577-81.

21.

Brain macrophage surface marker expression with HIV-1 infection and drug abuse: a preliminary study.

Shapshak P, Stewart RV, Rodriguez de la Vega P, Dominguez B, Fujimura R, Segal DM, Sun NC, Delgado S, Petito C.

J NeuroAIDS. 2002;2(3):37-50.

PMID:
16873198
22.

Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially initiate Toll-like receptor 4-dependent signal transduction pathways.

Wang ZY, Yang D, Chen Q, Leifer CA, Segal DM, Su SB, Caspi RR, Howard ZO, Oppenheim JJ.

Exp Hematol. 2006 Aug;34(8):1115-24.

PMID:
16863919
23.

Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling.

Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M, Hemming VG, Blanco JC, Segal DM, Vogel SN.

J Immunol. 2006 Jul 1;177(1):322-32.

24.

The dsRNA binding site of human Toll-like receptor 3.

Bell JK, Askins J, Hall PR, Davies DR, Segal DM.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8792-7. Epub 2006 May 23.

25.

The molecular structure of the Toll-like receptor 3 ligand-binding domain.

Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10976-80. Epub 2005 Jul 25.

26.

TLR9 is localized in the endoplasmic reticulum prior to stimulation.

Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM.

J Immunol. 2004 Jul 15;173(2):1179-83.

27.

A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4.

Kennedy MN, Mullen GE, Leifer CA, Lee C, Mazzoni A, Dileepan KN, Segal DM.

J Biol Chem. 2004 Aug 13;279(33):34698-704. Epub 2004 Jun 1.

28.

Controlling the Toll road to dendritic cell polarization.

Mazzoni A, Segal DM.

J Leukoc Biol. 2004 May;75(5):721-30. Epub 2004 Jan 14. Review.

PMID:
14726500
29.

Leucine-rich repeats and pathogen recognition in Toll-like receptors.

Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM.

Trends Immunol. 2003 Oct;24(10):528-33. Review.

PMID:
14552836
30.

Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent.

Huang LY, Aliberti J, Leifer CA, Segal DM, Sher A, Golenbock DT, Golding B.

J Immunol. 2003 Aug 1;171(3):1441-6.

31.

L-arginine metabolism in myeloid cells controls T-lymphocyte functions.

Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P.

Trends Immunol. 2003 Jun;24(6):302-6. Review.

PMID:
12810105
32.

The role of disulfide bonds in the assembly and function of MD-2.

Mullen GE, Kennedy MN, Visintin A, Mazzoni A, Leifer CA, Davies DR, Segal DM.

Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3919-24. Epub 2003 Mar 17.

33.

Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells.

Mazzoni A, Leifer CA, Mullen GE, Kennedy MN, Klinman DM, Segal DM.

J Immunol. 2003 Mar 1;170(5):2269-73.

34.

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P.

J Immunol. 2003 Jan 1;170(1):270-8.

35.

Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.

Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW.

Science. 2002 Nov 1;298(5595):1025-9.

36.

Axialization of laser cooled magnesium ions in a penning trap.

Powell HF, Segal DM, Thompson RC.

Phys Rev Lett. 2002 Aug 26;89(9):093003. Epub 2002 Aug 12.

37.

Toll-like receptor 1 inhibits Toll-like receptor 4 signaling in endothelial cells.

Spitzer JH, Visintin A, Mazzoni A, Kennedy MN, Segal DM.

Eur J Immunol. 2002 Apr;32(4):1182-7.

38.

Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM.

J Immunol. 2002 Jan 15;168(2):689-95.

39.

Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization.

Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM.

J Clin Invest. 2001 Dec;108(12):1865-73.

40.

Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4.

Visintin A, Mazzoni A, Spitzer JA, Segal DM.

Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12156-61. Epub 2001 Oct 2.

41.
42.

Introduction: bispecific antibodies.

Segal DM, Weiner GJ, Weiner LM.

J Immunol Methods. 2001 Feb 1;248(1-2):1-6. No abstract available.

PMID:
11223064
43.

Regulation of Toll-like receptors in human monocytes and dendritic cells.

Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM.

J Immunol. 2001 Jan 1;166(1):249-55.

44.

Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses.

Wyllie DH, Kiss-Toth E, Visintin A, Smith SC, Boussouf S, Segal DM, Duff GW, Dower SK.

J Immunol. 2000 Dec 15;165(12):7125-32.

45.

Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.

Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, Young HA, Zanovello P.

J Immunol. 2000 Dec 15;165(12):6723-30.

46.

Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).

Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA.

J Immunol. 2000 May 1;164(9):4433-42.

47.

Dopamine transporter mRNA in autopsy studies of chronic cocaine users.

Chen L, Segal DM, Moraes CT, Mash DC.

Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):181-5.

PMID:
10581411
48.

CD38 triggers cytotoxic responses in activated human natural killer cells.

Sconocchia G, Titus JA, Mazzoni A, Visintin A, Pericle F, Hicks SW, Malavasi F, Segal DM.

Blood. 1999 Dec 1;94(11):3864-71.

49.

Bispecific antibodies in cancer therapy.

Segal DM, Weiner GJ, Weiner LM.

Curr Opin Immunol. 1999 Oct;11(5):558-62. Review.

PMID:
10508714
50.

Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin.

Harari OA, Wickham TJ, Stocker CJ, Kovesdi I, Segal DM, Huehns TY, Sarraf C, Haskard DO.

Gene Ther. 1999 May;6(5):801-7.

Supplemental Content

Loading ...
Support Center